Biology subjects

Clement, L.

Publications and source records attributed to Clement, L..

4 recordsLinked to original sources

bioRxiv2018

Observation weights to unlock bulk RNA-seq tools for zero inflation and single-cell applications

Dropout events in single-cell transcriptome sequencing (scRNA-seq) cause many transcripts to go undetected and induce an excess of zero read counts, leading to power issues in differential expression (DE) analysis. This has triggered the development of bespoke scRNA-seq DE methods to cope with zero inflation. Recent evaluations, however, have shown that dedicated scRNA-seq tools provide no advantage compared to traditional bulk RNA-seq tools. We introduce a weighting strategy, based on a zero-inflated negative binomial (ZINB) model, that identifies excess zero counts and generates gene and cell-specific weights to unlock bulk RNA-seq DE pipelines for zero-inflated data, boosting performance for scRNA-seq.

bioinformatics↗

bioRxiv2017

zingeR: unlocking RNA-seq tools for zero-inflation and single cell applications

Dropout in single cell RNA-seq (scRNA-seq) applications causes many transcripts to go undetected. It induces excess zero counts, which leads to power issues in differential expression (DE) analysis and has triggered the development of bespoke scRNA-seq DE tools that cope with zero-inflation. Recent evaluations, however, have shown that dedicated scRNA-seq tools provide no advantage compared to traditional bulk RNA-seq tools. We introduce zingeR, a zero-inflated negative binomial model that identifies excess zero counts and generates observation weights to unlock bulk RNA-seq pipelines for zero-inflation, boosting performance in scRNA-seq differential expression analysis.

bioinformatics↗

bioRxiv2017

Mass spectrometrists should search for all peptides, but assess only the ones they care about

In shotgun proteomics identified mass spectra that are deemed irrelevant to the scientific hypothesis are often discarded. Noble (2015) 1 therefore urged researchers to remove irrelevant peptides from the database prior to searching to improve statistical power. We here however, argue that both the classical as well as Nobles revised method produce suboptimal peptide identifications and have problems in controlling the false discovery rate (FDR). Instead, we show that searching for all expected peptides, and removing irrelevant peptides prior to FDR calculation results in more reliable identifications at controlled FDR level than the classical strategy that discards irrelevant peptides post FDR calculation, or than Nobles strategy that discards irrelevant peptides prior to searching.

bioinformatics↗

bioRxiv2017

A general and powerful stage-wise testing procedure for differential expression and differential transcript usage

BackgroundReductions in sequencing cost and innovations in expression quantification have prompted an emergence of RNA-seq studies with complex designs and data analysis at transcript resolution. These applications involve multiple hypotheses per gene, leading to challenging multiple testing problems. Conventional approaches provide separate top-lists for every contrast and false discovery rate (FDR) control at individual hypothesis level. Hence, they fail to establish proper gene-level error control, which compromises downstream validation experiments. Tests that aggregate individual hypotheses are more powerful and provide gene-level FDR control, but in the RNA-seq literature no methods are available for post-hoc analysis of individual hypotheses.\n\nResultsWe introduce a two-stage procedure that leverages the increased power of aggregated hypothesis tests while maintaining high biological resolution by post-hoc analysis of genes passing the screening hypothesis. Our method is evaluated on simulated and real RNA-seq experiments. It provides gene-level FDR control in studies with complex designs while boosting power for interaction effects without compromising the discovery of main effects. In a differential transcript usage/expression context, stage-wise testing gains power by aggregating hypotheses at the gene level, while providing transcript-level assessment of genes passing the screening stage. Finally, a prostate cancer case study highlights the relevance of combining gene with transcript level results.\n\nConclusionStage-wise testing is a general paradigm that can be adopted whenever individual hypotheses can be aggregated. In our context, it achieves an optimal middle ground between biological resolution and statistical power while providing gene-level FDR control, which is beneficial for downstream biological interpretation and validation.

bioinformatics↗